Schedule 13G ownership disclosure

Amylyx Pharmaceuticals Inc

Common Stock, par value $0.0001 per share · CUSIP: 03237H101

Event date: 2025-06-24

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Point72 Asset Management, L.P.

    Shares: 4,717,709.00 · Class: 5.3%

  • Point72 Capital Advisors, Inc.

    Shares: 4,717,709.00 · Class: 5.3%

  • Steven A. Cohen

    Shares: 4,717,709.00 · Class: 5.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-25-002784
Form type
SCHEDULE 13G
Filer
Amylyx Pharmaceuticals, Inc.
CIK
CIK 1658551
Filed
Jun 25, 2025
Reporting period
Jun 24, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub